Inhibikase Therapeutics, Inc. · NASDAQ:IKT
Nantahala Capital Management, LLC reported a 5.68% stake in Inhibikase Therapeutics, Inc. (Schedule 13G/A)
Event Dec 31, 2025 · Filed Feb 13, 2026
Nantahala Capital Management, LLC reported a 5.68% stake in Inhibikase Therapeutics, Inc., 7,037,916 shares, as a passive investor on Dec 31, 2025. Filed Feb 13, 2026 (Schedule 13G/A).
- Stake
- 5.68%
- Shares
- 7,037,916
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 3 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Nantahala Capital Management, LLC | 5.68% | 7,037,916 |
| Wilmot B. Harkey | 5.68% | 7,037,916 |
| Daniel Mack | 5.68% | 7,037,916 |
Source
Related
- Inhibikase Therapeutics, Inc.
- Nantahala Capital Management, LLC
- Inhibikase Therapeutics, Inc. shareholders
- Schedule 13G/A · Nantahala Capital Management, LLC · Aug 14, 2026
- Schedule 13G · Nantahala Capital Management, LLC · Feb 14, 2025
- Schedule 13G/A · Perceptive Advisors LLC · Aug 14, 2026
- Schedule 13G/A · Sands Capital Life Sciences Pulse Fund II, L.P. · Aug 13, 2026
- Form 4 · Berman Dennis N · Jul 31, 2026
- Form 4 · RA Capital Healthcare Fund LP · Jul 31, 2026
- Schedule 13G/A · Ra Capital Management, L.P. · Jul 31, 2026